SG11201903063UA - Anti-o1 antibodies and uses thereof - Google Patents

Anti-o1 antibodies and uses thereof

Info

Publication number
SG11201903063UA
SG11201903063UA SG11201903063UA SG11201903063UA SG11201903063UA SG 11201903063U A SG11201903063U A SG 11201903063UA SG 11201903063U A SG11201903063U A SG 11201903063UA SG 11201903063U A SG11201903063U A SG 11201903063UA SG 11201903063U A SG11201903063U A SG 11201903063UA
Authority
SG
Singapore
Prior art keywords
llc
way
gaithersburg
medimmune
maryland
Prior art date
Application number
SG11201903063UA
Inventor
Qun Wang
Charles K Stover
Meghan Pennini
Chew-Shun Chang
Xiaodong Xiao
Jamese Hilliard
Gilad Kaplan
Davide Corti
Elisabetta Cameroni
Martina Beltramello
Original Assignee
Medimmune Llc
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Humabs Biomed Sa filed Critical Medimmune Llc
Publication of SG11201903063UA publication Critical patent/SG11201903063UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26—Klebsiella (G)

Abstract

FIGA LPS-01 ELISA KP.A27 -e- 59H7 - KPB202 KPE 33 K1 7 .1 mAla concentration [ngimi] W O 20 18/075 375 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT omit VIII °nolo ovilioillinnovoimIE (10) International Publication Number WO 2018/075375 Al (51) International Patent Classification: C07K 16/12 (2006.01) A61K 39/40 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2017/056725 (22) International Filing Date: 16 October 2017 (16.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/410,005 19 October 2016 (19.10.2016) US (71) Applicants: MEDIMMUNE, LLC [US/US]; One Medlm- mune Way, Gaithersburg, Maryland 20878 (US). HUM- ABS BIOMED SA [CH/CH]; Mirasole 1, CH-6500 Bellinzona (CH). (72) Inventors: WANG, Qun; MedImmune, LLC, One Medlm- mune Way, Gaithersburg, 20878 (US). STOVER, Charles K.; Medlmmune, LLC, One MedImmune Way, Gaithers- burg, Maryland 20878 (US). PENNINI, Meghan; Medlm- mune, LLC, One MedImmune Way, Gaithersburg, Mary- land 20878 (US). CHANG, Chew-Shun; Medlmmune, LLC, One Medlmmune Way, Gaithersburg, Maryland 20878 (US). XIAO, Xiaodong; Medlmmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). HILLIARD, Jamese; Medlmmune, LLC, One MedIm- mune Way, Gaithersburg, Maryland 20878 (US). KA- PLAN, Gilad; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). CORTI, Davide; Humabs BioMed SA, Mirasole 1, CH-6500 Bellinzona (CH). CAMERONI, Elisabetta; Humabs BioMed SA, Mirasole 1, CH-6500 Bellinzona (CH). BELTRAMEL- LO, Martina; Humabs BioMed SA, Mirasole 1, CH-6500 Bellinzona (CH). (74) Agent: MARTIN, Cynthia Lan et al.; MedImmune, LLC, One Medlmmune Way, Gaithersburg, Maryland 20878 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: ANTI-01 ANTIBODIES AND USES THEREOF (57) : The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae 01 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or pre- venting Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising adminis- tering the Klebsiella pneumoniae 01 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject. FIG. 1B SBA of 4211-lux 0^ 10° 10' 10' 10 0 mAb concentration [ngimi] FIG. 1C OPK of 43816dCpsB 10' 10' BM 10. 10' 10' 10. 10' mAlt concentration [ngimi] [Continued on next page] 100 ▪ 50 100 0 KPA27 ▪ 54H7 - KPB202 KPE33 A- K1,14 KPA2] -a- 54H7 KPB202 ▪ KPE33 KI 7 .14 WO 2018/075375 Al MIDEDIMOMOIDEIREIDIONOMINOMEOMEMOIMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201903063UA 2016-10-19 2017-10-16 Anti-o1 antibodies and uses thereof SG11201903063UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410005P 2016-10-19 2016-10-19
PCT/US2017/056725 WO2018075375A1 (en) 2016-10-19 2017-10-16 Anti-o1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201903063UA true SG11201903063UA (en) 2019-05-30

Family

ID=62019658

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903063UA SG11201903063UA (en) 2016-10-19 2017-10-16 Anti-o1 antibodies and uses thereof

Country Status (12)

Country Link
US (2) US11117956B2 (en)
EP (1) EP3529273A4 (en)
JP (1) JP7160484B2 (en)
KR (1) KR20190064636A (en)
CN (1) CN109843917B (en)
AU (1) AU2017346488A1 (en)
BR (1) BR112019007147A2 (en)
CA (1) CA3039686A1 (en)
EA (1) EA201990895A1 (en)
IL (1) IL266049A (en)
SG (1) SG11201903063UA (en)
WO (1) WO2018075375A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190077306A (en) 2016-08-05 2019-07-03 메디뮨 엘엘씨 Anti-O2 antibodies and uses thereof
KR20190064636A (en) 2016-10-19 2019-06-10 메디뮨 엘엘씨 Anti-O1 antibodies and uses thereof
CN114206371A (en) * 2019-06-06 2022-03-18 诺麦生物科学有限公司 Klebsiella for controlling Klebsiella
WO2021186398A1 (en) 2020-03-19 2021-09-23 Medimmune Limited Anti-klebsiella pneumoniae antibodies and uses thereof
WO2023025173A1 (en) * 2021-08-25 2023-03-02 舒泰神（北京）生物制药股份有限公司 Antibody capable of specifically recognizing klebsiella pneumoniae o1 antigen and use thereof
WO2023103788A1 (en) * 2021-12-06 2023-06-15 北京三诺佳邑生物技术有限责任公司 Bispecific antibody that specifically binds to klebsiella pneumoniae o2 and o1 antigens, and composition

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5179018A (en) 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (en) 1987-03-18 1999-04-22 Sb2 Inc CHANGED ANTIBODIES.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
EP0553244B8 (en) 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (en) 1990-10-29 1997-12-15 Chiron Corp BISPECIFIC ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech Inc METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
PT627940E (en) 1992-03-05 2003-07-31 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZED TUMORS
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69621940T2 (en) 1995-08-18 2003-01-16 Morphosys Ag PROTEIN - / (POLY) PEPTIDE LIBRARIES
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2386574A3 (en) 1999-01-15 2012-06-27 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
ATE482275T1 (en) 1999-07-02 2010-10-15 Morphosys Ag GENERATION OF SPECIFIC BINDING PARTNERS THAT BIND TO (POLY)PEPTIDES ENCODED BY GENOMIC DNA FRAGMENTS OR ESTS
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
TWI503328B (en) * 2003-07-15 2015-10-11 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
RS54393B1 (en) 2005-09-07 2016-04-28 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
BR112012013502A2 (en) 2009-12-06 2017-01-10 Biogen Idec Hemophilia Inc "chimeric and hybrid factor viii-fc polypeptides, and methods of using them".
PT2591006T (en) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Processable single chain molecules and polypeptides made using same
MY170407A (en) 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
WO2014027697A1 (en) * 2012-08-13 2014-02-20 Kyowa Hakko Kirin Co., Ltd. Anti-pneumococcal surface protein (psp) monoclonal antibody
JP6419076B2 (en) 2012-10-05 2018-11-14 カドモン コーポレイション，リミティド ライアビリティ カンパニー RHO kinase inhibitor
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
MX2017009955A (en) * 2015-02-17 2017-10-19 Arsanis Biosciences Gmbh Antibodies targeting a galactan-based o-antigen of k. pneumoniae.
CA2995387A1 (en) 2015-08-24 2017-03-02 Medimmune, Llc Mrka polypeptides, antibodies, and uses thereof
CA3000901A1 (en) * 2015-10-16 2017-04-20 Arsanis Biosciences Gmbh Bactericidal monoclonal antibody targeting klebsiella pneumoniae
KR20190077306A (en) 2016-08-05 2019-07-03 메디뮨 엘엘씨 Anti-O2 antibodies and uses thereof
KR20190064636A (en) 2016-10-19 2019-06-10 메디뮨 엘엘씨 Anti-O1 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3039686A1 (en) 2018-04-26
WO2018075375A1 (en) 2018-04-26
BR112019007147A2 (en) 2019-06-25
US11117956B2 (en) 2021-09-14
US20200231660A1 (en) 2020-07-23
EP3529273A1 (en) 2019-08-28
CN109843917A (en) 2019-06-04
JP7160484B2 (en) 2022-10-25
JP2020500005A (en) 2020-01-09
EP3529273A4 (en) 2020-07-01
AU2017346488A1 (en) 2019-05-30
US20220056113A1 (en) 2022-02-24
KR20190064636A (en) 2019-06-10
CN109843917B (en) 2023-10-03
EA201990895A1 (en) 2019-10-31
IL266049A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
SG11201903063UA (en) Anti-o1 antibodies and uses thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201809643UA (en) Compositions and methods of treating huntington's disease
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807912SA (en) Vaccine against rsv
SG11201906341XA (en) Improved serum albumin binders
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201900027XA (en) Anti-o2 antibodies and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201903287PA (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201807523PA (en) Ilt7 binding molecules and methods of using the same